The Future of Pharmaceuticals and the FDA Pipeline

Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.

Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.

Landmon went into further detail on upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.